At visibility of outgrowing HBDC, the medium was changed every 3 days.
HBDC, SaOs-2, or MG-63 cells were seeded on the different porous and mirror-polished (control) specimens in a density of 5 x [10.sup.4] cells/sample in 50 [micro]L medium in beforehand agarose coated 24-well plates.
MTT assays were carried out with two bone cell lines (SaOs-2 and MG-63) and with one bone-primary cell type (human bone-derived cells, HBDC) for each porous material (with n = 4) to study cell reactions (i.e., viability) either after one day or three days of culture.
HBdC, SaOs-2, and MG-63 viabilities are also enhanced after 3 days of culture (Figure 4(a)).
The MTT results (Figure 4(a)) of HBDC and MG-63 after one day show similar results, whereas the values for SaOs-2 on materials control ("Co") and "Small" are decreased.
The new venture called Co-Diagnostics HBDC
LLC will sell testing products based on technology developed by DNA Logix and licensed to the JV, as well as provide services to middle- and low-income countries.
23 August 2013 - US nonprofit organisation Mentors International and Co-Diagnostics HBDC have agreed to reduce the prices of real-time PCR tests in the developing world, starting with tuberculosis, the parties said today.
Under the deal, Co-Diagnostics HBDC will provide low-cost testing reagents, while the organisation will use its international connections to establish low-cost testing facilities.
Co-Diagnostics HBDC is a joint venture between US molecular diagnostics company Co-Diagnostics Inc and DNA testing specialist DNA Logix Inc, focused on provision of diagnostic products for infectious diseases to high-burden developing countries (HBDC).
The new entity, Co-Diagnostics HBDC LLC, will be engaged in the sale of testing products and services based on DNA Logix's real-time PCR testing technology which it licensed to the JV.
It has been estimated that 90% of the global disease burden occurs in HBDC.